End Stage Cancer clinical trials at UCSD

1 research study open to eligible people

Showing trials for

  • Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

    open to eligible people ages 18 years and up

    This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor [Retifanlimab], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no approved alternative therapies available.

    San Diego, California and other locations

Our lead scientists for End Stage Cancer research studies include .

Last updated: